• Keine Ergebnisse gefunden

Supplementary Table S1.

N/A
N/A
Protected

Academic year: 2022

Aktie "Supplementary Table S1."

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Supplementary Table S1. Sensitivity analysis using different testing kit costs for drug levels and antidrug antibody formation.

Testing kit cost, € Total cost, € QALY Incremental Cost (IG-CG)

Incremental

QALY (IG-CG) ICER

DL ADA CG IG CG IG

16

10

17,37

8 15,312 1.076 1.161 -2066 0.085 Dominant

25

20

17,37

8 15,364 1.076 1.161 -2014 0.085 Dominant

35

30

17,37

8 15,423 1.076 1.161 -1955 0.085 Dominant

Abbreviations: DL: drug level; ADA: antidrug antibody formation; CG, control group; IG: intervention group;

QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.

Referenzen

ÄHNLICHE DOKUMENTE

Abbreviations: M, male; F, female; IgG4-RD, IgG4-related disease; DLBCL, diffuse large B cell lymphoma; MM, multiple myeloma; HL, Hodgkin’s lymphoma; FL, follicular lymphoma;

Frequency of distinct types of imaging tests performed during the first year after the first visit to the pediatric rheumatologist in patients with a complete year of observation

False positive category of symptoms that did not correlate with enzyme elevation includes cases where there was no temporal association as well as cases that were confounded by

SCLC, small cell lung cancer; LND, lymph node dissected; LNM, lymph node metastasis; NO*, no lymph node dissected.. Supplementary

(((((((((((((((((((((rheumatoid) AND pannus)) OR (((rheumatoid) AND fibroblast) AND synovial)) OR ((rheumatoid) AND purpura)) OR ((rheumatoid) AND vasculitis)) OR ((rheumatoid)

bDMARD, biologic disease-modifying antirheumatic drug; COVID-19, the 2019 novel coronavirus

Kaplan-Meier plot demonstrating 6-month all-cause mortality by timing of cryptococcal antigen (CrAg) testing and outpatient/inpatient status at the time of HIV diagnosis among people

FTO CCAGAACCTGAGGAGAGAATGG CGATGTCTGTGAGGTCAAACGG ALKBH5 CCAGCTATGCTTCAGATCGCCT GGTTCTCTTCCTTGTCCATCTCC ALPL GCTGTAAGGACATCGCCTACCA CCTGGCTTTCTCGTCACTCTCA RUNX2